Our products enable radiologists and pathologists to diagnose more quickly and surgeons to operate more efficiently. We are thrilled to be able to bring our technology to Brazil to support opinion leading institutions and their patients.
Tucson, Arizona (PRWEB) March 17, 2013
Faxitron today announced that the Brazilian National Health Surveillance Agency ANVISA (Agencia Nacional de Vigilancia Sanitaria) has approved their leading-edge technology for clinical use and commercialization in Brazil. Faxitron’s Intraoperative Specimen Radiography System, BioVision, and Stereotactic Core Biopsy Specimen Radiography System, CoreVision, greatly enhance the standard of patient care and improve operational efficiency in the diagnosis of breast cancer.
Paul Murtagh, Faxitron’s CEO, stated: “The ANVISA medical device certification allows us to play a central role in the critical ‘standard of care’ chain in breast cancer. Our products enable radiologists and pathologists to diagnose more quickly and surgeons to operate more efficiently. We are thrilled to be able to bring our technology to Brazil to support opinion leading institutions and their patients”.
Brazil has the largest economy and medical device market in Latin America, and there is an ever growing need for specialized imaging technology such as the BioVision and CoreVision to improve the overall quality of care for the patients.
Faxitron is the world’s largest and only fully vertically integrated, dedicated cabinet x-ray company. With an installed base of over 7,000 systems in medical facilities and scientific and industrial research laboratories around the globe, Faxitron is the pioneer and industry standard in cabinet x-ray systems for specimen radiography, research, and NDT applications. For more than 40 years, Faxitron has defined cabinet x-ray by developing x-ray sensor technology and innovative systems to meet the evolving needs of our customers. For more information, please visit http://www.faxitron.com.